Drug

Ziltivekimab

In clinical development

ClassInterleukin-6 inhibitorEmerging researchLate-stage development

Also known as Immunoglobulin g1 (255-tyrosine,257-threonine,259-glutamic acid), anti-(human interleukin 6) (human monoclonal 2e2.3a9.6a3 .gamma.1-chain), disulfide with human monoclonal 2e2.3a9.6a3 .kappa.-chain, dimer.

RxNorm2686459 ChEMBLCHEMBL4297732UNIIAN3Y2B4SX4

Research papers

Active clinical trials

Interleukin-6

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Clinical trial2026-07-07Results expected Q3 2027 · ClinicalTrials.gov

Specifying the Anti-inflammatory Effects of Ziltivekimab With Diverse Imaging Modalities and In-depth Cellular Phenotyping

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody-Mediated Interleukin-6 Inhibition in Japan

Clinical trial2026-05-06Results posted · ClinicalTrials.gov

ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

Clinical trial2026-04-14Results expected Q4 2026 · ClinicalTrials.gov

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Clinical trial2026-04-07Results expected Q4 2026 · ClinicalTrials.gov

Effects of Ziltivekimab Versus Placebo on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-infrared Spectroscopy and Optical Coherence Tomography Imaging Study

Clinical trial2026-03-23Results expected Q3 2028 · ClinicalTrials.gov

Clinical trial2026-03-11Results expected Q4 2028 · ClinicalTrials.gov

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Clinical trial2025-12-31Results posted · ClinicalTrials.gov

Pharmacokinetics, Pharmacodynamics and Safety of Ziltivekimab Versus Placebo in Chinese Participants With Chronic Kidney Disease and Systemic Inflammation

Clinical trial2024-09-02Completed · ClinicalTrials.gov

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.

Research2021-05-17Circulation research

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Ziltivekimab

Aliases & brands

Immunoglobulin g1 (255-tyrosine,257-threonine,259-glutamic acid), anti-(human interleukin 6) (human monoclonal 2e2.3a9.6a3 .gamma.1-chain), disulfide with human monoclonal 2e2.3a9.6a3 .kappa.-chain, dimer

RxNorm CUI

2686459

ChEMBL ID

CHEMBL4297732

UNII

AN3Y2B4SX4

Primary mechanism

Interleukin-6 inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Interleukin-6

IL6 · P05231

INHIBITORInterleukin-6 inhibitor

Clinical trials

9 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2024

Active studies

Recruiting

Late-stage (III+)

Completed

PHASE DISTRIBUTIONn = 9

Phase 11Phase 22Phase 36

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

RecruitingPH IIINovo Nordisk A/Sn=3322029

RecruitingPH IIIECRI bvn=3322028

Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Active, not recruitingPH IIIKey trialNovo Nordisk A/Sn=4,8992027

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

RecruitingPH IIINovo Nordisk A/Sn=6802027

ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction

RecruitingPH IIIKey trialNovo Nordisk A/Sn=10,0002026

Recent completions

Trials that read out recently, adding to the completed evidence base.

Pharmacokinetics, Pharmacodynamics and Safety of Ziltivekimab Versus Placebo in Chinese Participants With Chronic Kidney Disease and Systemic Inflammation

CompletedPH INovo Nordisk A/Sn=242024

CompletedPH IINovo Nordisk A/Sn=362021

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

CompletedPH IINovo Nordisk A/Sn=2642020

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease.

Circulation research · 2021 · 459 cites

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Canakinumab

Studied across 8 of the same disease areas as Ziltivekimab in the shared literature.

8 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials